Reaction

Pancreatic Carcinoma Metastatic reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,820 reports · 86 co-occurring drugs

As of the last recalculation, Pancreatic Carcinoma Metastatic appears in 2,820 FAERS reports alongside 86 co-occurring drug terms. The strongest observed disproportionality signal is SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (PRR 78.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Sitagliptin And Metformin Hydrochloride	212	78.4	79.1
Sitagliptin	531	66.8	67.2
Gemcitabine	269	55.6	56.0
Exenatide	329	52.1	52.4
Liraglutide	283	46.9	47.1
Gemcitabine Hydrochloride	299	46.4	46.7
Pancrelipase	200	41.1	41.3
Paclitaxel	333	28.0	28.1
Erlotinib Hydrochloride	43	25.7	25.8
Dronabinol	18	16.6	16.7
Erlotinib	20	15.3	15.4
Prochlorperazine Maleate	16	12.9	12.9
Pioglitazone	73	12.8	12.8
Oxaliplatin	116	12.0	12.0
Glyburide	37	11.4	11.4
Diphenoxylate Hydrochloride And Atropine Sulfate	19	10.3	10.3
Fluorouracil Cream, 0.5%	99	9.9	9.9
Glimepiride	51	9.8	9.8
Fluorouracil	99	9.8	9.8
Valsartan And Hydrochlorothiazide	17	9.3	9.3
Glipizide	73	9.1	9.1
Ezetimibe And Simvastatin	17	8.3	8.3
Insulin Aspart	71	8.1	8.1
Niacin	12	7.7	7.7
Enoxaparin Sodium	57	7.4	7.4
Insulin	54	7.3	7.3
Clotrimazole	12	7.2	7.2
Human Insulin	12	7.1	7.1
Sennosides 8.6 Mg Tablets	20	7.1	7.1
Meclizine Hcl 12.5Mg	13	7.1	7.1
Meclizine Hcl 25Mg	13	7.1	7.1
Meclizine Hcl 12.5 Mg	13	7.1	7.1
Meclizine Hcl 25 Mg	13	7.1	7.1
Drs. Clotrimazole	11	7.0	7.1
Family Wellness Clotrimazole	11	7.0	7.1
Senna	20	7.0	7.1
Clotrimazole Topical	11	7.0	7.1
Senna Leaf	21	6.8	6.8
Metformin Er 500 Mg	247	6.5	6.6
Metformin Er 750 Mg	247	6.5	6.6
Metformin	287	6.5	6.5
Fondaparinux Sodium	7	6.4	6.4
Atropine Sulfate	9	6.2	6.2
Cholestyramine	10	6.1	6.1
Capecitabine	72	5.9	5.9
Meclizine	13	5.9	5.9
Insulin Glargine	186	5.9	5.9
Insulin Glulisine	8	5.8	5.8
Metformin Hydrochloride	46	5.8	5.8
Insulin Glargine-Yfgn	17	5.8	5.8
Irinotecan Hydrochloride	10	5.8	5.8
Irbesartan	34	5.7	5.7
Paclitaxel (Aibumin-Bound)	62	5.7	5.7
Prochlorperazine	21	5.6	5.6
Amlodipine Besylate And Benazepril Hydrochloride	7	5.6	5.6
Metformin Hydrochloride Tablets	42	5.5	5.5
Metformin Hydrochloride Extended-Release Tablets	42	5.5	5.5
Metformin Hydrochloride Tablet	42	5.5	5.5
Sennosides	22	5.5	5.5
Metformin Hcl	40	5.4	5.4
Gemfibrozil	11	5.4	5.4
Dulaglutide	58	4.9	4.9
Loperamide Hydrochloride And Dimethicone	21	4.9	4.9
Fenofibrate	23	4.8	4.8
Metoclopramide Hydrochloride	49	4.8	4.8
Insulin Degludec	15	4.7	4.7
Ondansetron	67	4.6	4.6
Ondansetron Tablets	67	4.6	4.6
Benzonatate	10	4.5	4.5
Oral Semaglutide	44	4.5	4.5
Aprepitant	11	4.4	4.4
Trametinib	14	4.3	4.3
Granisetron Hydrochloride	6	4.2	4.2
Linagliptin	10	4.1	4.1
Fosaprepitant Dimeglumine	7	3.8	3.8
Insulin Lispro	69	3.8	3.8
Romiplostim	7	3.4	3.4
Panitumumab	7	3.3	3.3
Cisplatin	33	3.1	3.1
Canagliflozin	12	3.0	3.0
Prasugrel Hydrochloride	4	2.9	2.9
Ranolazine	4	2.8	2.8
Pemetrexed	8	2.8	2.8
Siponimod	3	2.5	2.5
Fam-Trastuzumab Deruxtecan-Nxki	3	2.2	2.2
Osimertinib	8	1.8	1.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.